Myocardial infarction in diffuse large B-cell lymphoma patients - a population-based matched cohort study

Area of Science:

• Cardiology
• Oncology
• Epidemiology

Background:

• Immunochemotherapy like R-CHOP has improved diffuse large B-cell lymphoma (DLBCL) outcomes.
• While heart failure is a known complication, other cardiac issues like myocardial infarction (MI) are less understood.
• This study investigates the incidence and outcomes of acute myocardial infarctions (AMIs) in DLBCL patients.

Purpose of the Study:

• To determine the incidence and characteristics of acute myocardial infarctions (AMIs) in patients treated for diffuse large B-cell lymphoma (DLBCL).
• To compare AMI rates and outcomes between DLBCL patients and the general population.
• To identify risk factors for AMI in DLBCL survivors.

Main Methods:

• A population-based cohort study in Sweden identified 3548 DLBCL patients and 35474 matched controls.
• Data from national registers were used to assess AMI incidence, characteristics, and outcomes up to 11 years post-diagnosis.
• Flexible parametric models were employed to estimate AMI rates.

Main Results:

• DLBCL patients exhibited a 33% excess rate of AMI compared to the general population (HR: 1.33).
• The elevated AMI risk was most pronounced within the first year and decreased after two years.
• Older age, male sex, and comorbidities were significant risk factors; older patients with mild comorbidities had a 61% higher AMI rate.

Conclusions:

• Diffuse large B-cell lymphoma patients have an increased risk of acute myocardial infarction, particularly in the initial two years post-diagnosis.
• Enhanced cardiac monitoring, tailored to patient age and comorbidities, is recommended.
• No significant differences were observed in AMI management or survival between DLBCL patients and controls.